Every material Form 8-K Tectonic Therapeutic, Inc. has filed with the SEC since August 06, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Tectonic Therapeutic reported third-quarter 2026 results in an 8-K that furnished its press release. The net loss widened year over year, driven by higher research and development and general and administrative spending, while the company reported favorable Phase 1a safety and pharmacokinetic results for TX2100 and said cash should fund operations into Q1 2029.
Net loss of $21.3 million, or $1.08 per share, for the three months ended September 30, 2026, versus $19.0 million, or $1.02 per share, a year earlier.
Research and development expenses rose to $17.4 million from $16.9 million; general and administrative expenses rose to $6.0 million from $5.0 million.
Cash and cash equivalents were $234.7 million at September 30, 2026, down from $253.8 million at December 31, 2025.
Topline results from the APEX Phase 2 trial of TX45 in PH-HFpEF are expected by the end of January 2027.
Tectonic Therapeutic reported topline Phase 1a results for TX2100, an investigational antibody for hereditary hemorrhagic telangiectasia (HHT), stating the drug was generally safe and well-tolerated in healthy adult volunteers. The FDA also granted TX2100 Fast Track designation for HHT and cleared the IND for a planned Phase 1b trial, which advances the clinical program toward patients. The filing discloses no revenue or financial results, and anti-drug antibody results remain pending.
Phase 1a enrolled 48 healthy adult volunteers across six dose cohorts; no deaths, serious adverse events or severe treatment-emergent adverse events were reported at any dose
FDA cleared the IND in August 2026 and granted Fast Track designation in September 2026
Phase 1b trial in HHT patients planned to begin by year-end 2026; Phase 2 planned to begin in early 2027
Detailed Phase 1a results to be presented at the CureHHT 16th HHT International Scientific Conference, October 12-16, 2026
Tectonic Therapeutic reported second-quarter 2026 results, with a net loss of $22.3 million, up from $20.0 million a year earlier, as research and development and general and administrative expenses rose. Cash and cash equivalents fell to $227.1 million from $236.9 million at March 31, 2026, and the company expects that cash to fund operations into Q1 2029.
Net loss of $22.3 million for the three months ended June 30, 2026, versus $20.0 million a year earlier; net loss per share of $1.18 versus $1.07
R&D expenses rose to $18.0 million from $17.2 million, mainly due to Phase 2 trial costs and stock-based compensation
Cash and cash equivalents of $227.1 million at June 30, 2026, with cash runway expected into Q1 2029
TX45 APEX Phase 2 trial completed enrollment in June 2026, with topline results expected in early Q1 2027
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Tectonic Therapeutic, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →